Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin Therapy for Fibromyalgia
NCT05128162Phase 2Completed
- Start
- Sep 2023
- Primary completion
- Jun 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of psilocybin in fibromyalgia (FM). Primary endpoints: Heart Rate Beats Per Minute (BPM), Systolic and Diastolic Blood Pressure and 1 more. Started Sep 2023; status: completed.
02
Drugs
psilocybin
03
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on NCT05128162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05128162.